Xevinapant Explained

Legal Status:	Investigational
Cas Number:	1071992-99-8
Pubchem:	25022340
Drugbank:	DB16305
Chemspiderid:	28424114
Unii:	N65WC8PXDD
Kegg:	D12565
Chembl:	2158051
Synonyms:	AT 406; Debio-1143
Iupac Name:	(5S,8S,10aR)-N-benzhydryl-5-(2S)-2-(methylamino)propanoylamino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide\| C=32 \| H=43 \| N=5 \| O=4\| SMILES = C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC\| StdInChI = 1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1\| StdInChIKey = LSXUTRRVVSPWDZ-MKKUMYSQSA-N

Xevinapant is an investigational new drug that is being evaluated to treat squamous cell cancer.^[1] By acting as a SMAC mimetic, it functions as an inhibitor of several members of the IAP protein family (including XIAP, c-IAP1, and c-IAP2).^[2]

Notes and References

Web site: Xevinapant - Merck & Co . AdisInsight . Springer Nature Switzerland AG .
Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, Schroeder A, Bourhis J . Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck . Cancer Treatment Reviews . 113 . 102492 . February 2023 . 36640618 . 11227656 . 10.1016/j.ctrv.2022.102492 .